USA - NASDAQ:TNXP - US8902608392 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to TNXP. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-20 | Noble Capital Markets | Reiterate | Outperform -> Outperform |
| 2024-07-22 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-02-28 | Dawson James | Initiate | Buy |
| 2023-08-01 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-06-02 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-01-12 | Alliance Global Partners | Reiterate | Buy |
| 2022-04-18 | Noble Capital Markets | Initiate | Outperform |
8 analysts have analysed TNXP and the average price target is 69.02 USD. This implies a price increase of 239.16% is expected in the next year compared to the current price of 20.35.
The consensus rating for TONIX PHARMACEUTICALS HOLDIN (TNXP) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.